Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?

Leslie Cho; Andrew M Kaunitz; Stephanie S Faubion; Sharonne N Hayes; Emily S Lau; Nicole Pristera; Nandita Scott; Jan L Shifren; Chrisandra L Shufelt; Cynthia A Stuenkel; Kathryn J Lindley; ACC CVD in Women Committee

doi:10.1161/CIRCULATIONAHA.122.061559

Therapeutics · Hormonal Agents

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?

Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, Scott N, Shifren JL, Shufelt CL, Stuenkel CA, Lindley KJ, ACC CVD in Women Committee

Published February 14, 2023 Circulation, 147(7), 597-610

DOI 10.1161/CIRCULATIONAHA.122.061559 PMID 36780393 PMC PMC10708894

Abstract

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

Topics

Therapeutics › Hormonal Agents › Estrogen Preparations · Perimenopause and Menopause › Hormone Therapy › Benefits and Risks

Leslie Cho, Andrew M Kaunitz, Stephanie S Faubion, Sharonne N Hayes, Emily S Lau, Nicole Pristera, Nandita Scott, Jan L Shifren, Chrisandra L Shufelt, Cynthia A Stuenkel, Kathryn J Lindley

L Cho, Andy Kaunitz, Drew Kaunitz, A Kaunitz, S Faubion, S Hayes, E Lau, N Pristera, N Scott, J Shifren, C Shufelt, C Stuenkel, Kathy Lindley, Kate Lindley, K Lindley

PMID 36780393 36780393 DOI 10.1161/CIRCULATIONAHA.122.061559 10.1161/CIRCULATIONAHA.122.061559 Cho et al. 2023, Cho 2023

Keywords

cardiovascular diseases, coronary artery disease, hormone replacement therapy, hyperlipidemias, hypertension, menopause, venous thromboembolism

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?

Abstract

Topics

By this author

Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials

Association of infertility with atherosclerotic cardiovascular disease among postmenopausal participants in the Women's Health Initiative

Related research

Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses

[Hormone replacement therapy of menopause, heart and blood vessels]

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial

Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence

Keywords